Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
BUSINESS
MSD Japan Chief Flags Re-Pricing for Keytruda, Says It’s “Heading into That Range”
US Merck’s immuno-oncology star Keytruda (pembrolizumab) is chalking up bullish growth in Japan just as in the global market, but as such, it is nearing the range where its sales could invoke the government’s re-pricing rule, MSD Japan President Jannie…
To read the full story
Related Article
- Keytruda Faces Price Slash on Better-than-Expected Sales
November 12, 2019
- Keytruda Boon Aside, MSD Japan Mulls Job Cuts for Sales and Marketing
September 4, 2019
- Supply of MSD’s Hep B Vaccine Heptavax Might Be Suspended as Early as October: MHLW
April 10, 2019
- Kyorin Introduces Voluntarily Recall of Desalex
January 9, 2019
- Re-Pricing Rule for Indication Expansions Mars I/O Development: MSD Japan Chief
March 14, 2018
BUSINESS
- All Versions of Lilly’s Strattera under Restricted Supplies in Japan
November 26, 2024
- ASKA, Renascience Wind Up PMS Drug Collab after PII Miss
November 26, 2024
- Kyowa Kirin Recalls Regpara after Nitrosamine Detection
November 25, 2024
- Keytruda, Arexvy, Imfinzi, Lynparza Broaden Labels in Japan
November 25, 2024
- Otsuka Bags Worldwide Rights to Ionis’ ALS Drug
November 25, 2024
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…